教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. |
掲載誌名 | 正式名:Atherosclerosis 略 称:Atherosclerosis ISSNコード:1879-1484(Electronic)0021-9150(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 251,pp.367-72 |
著者・共著者 | Tsujita Kenichi, Yamanaga Kenshi, Komura Naohiro, Sakamoto Kenji, Sugiyama Seigo, Sumida Hitoshi, Shimomura Hideki, Yamashita Takuro, Oka Hideki, Nakao Koichi, Nakamura Sunao, Ishihara Masaharu, Matsui Kunihiko, Sakaino Naritsugu, Nakamura Natsuki, Yamamoto Nobuyasu, Koide Shunichi, Matsumura Toshiyuki, Fujimoto Kazuteru, Tsunoda Ryusuke, Morikami Yasuhiro, Matsuyama Koushi, Oshima Shuichi, Kaikita Koichi, Hokimoto Seiji, Ogawa Hisao, Ogawa Hisao |
発行年月 | 2016/08 |
概要 | BACKGROUND AND AIMS:Although dual low-density lipoprotein cholesterol (LDL-C)-lowering therapy (DLLT) with statin-ezetimibe combination showed clinical benefit in patients with acute coronary syndrome (ACS) confirmingBACKGROUND AND AIMS:"BACKGROUND AND AIMS:the lower, the better,BACKGROUND AND AIMS:"BACKGROUND AND AIMS:the underlying mechanisms of DLLT are still unknown.METHODS:PRECISE-IVUS trial evaluated the effects of DLLT on IVUS-derived coronary atherosclerosis and lipid profile, compared with atorvastatin monotherapy, quantifyingMETHODS:the coronary plaque response in 100 ACS patients. We explored the potential predictors of plaque regression.RESULTS:Lower total cholesterol, LDL-C, triglyceride, remnant-like particles cholesterol, and stronger reduction of small dense LDL-C and cholesterol absorption markers were observed in patients with plaque regression compared to those with progression. Multivariate analysis revealed that achieved LDL-C was the strongest predictor for coronary plaque regression (95% CI: 0.944-1.000, p = 0.05), followed by age (95% CI: 0.994-1.096, p = 0.09).CONCLUSIONS:Incremental LDL-C lowering by DLLT was associated with stronger coronary plaque regression, reconfirming that lowering LDL-C to levels below previous targets provided additional clinical benefit. |
DOI | 10.1016/j.atherosclerosis.2016.05.025 |
PMID | 27318866 |